Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Drug: Pacritinib for Myelofibrosis
Study: International, multicenter, randomized, double-blind trial (PERSIST-2) Intermediate-1, intermediate-2, or high-risk disease myelofibrozis Pacritinib 400 mg (n=75) vs pacritinib 200 mg BID (n=74) vs BAT (n=72 Efficacy: >35% spleen volume
New Protocol: Darolutamide in Metastatic, Hormone-Sensitive Prostate Cancer
Study: International, multicenter, phase 3 trial (ARASENS) Metastatic, hormone-sensitive prostate cancer Darolutamide (n=651) or placebo (n=654) with androgen-deprivation therapy and docetaxel. Efficacy: Median treatment duration: 41 m vs 16.7 months
New Protocol: Pembrolizumab in Early Triple-Negative Breast Cancer
Study: Randomized, double-blind, placebo-controlled trial (KEYNOTE-522) Previously untreated stage II or III triple-negative breast cancer Neoadjuvant/adjuvant pembrolizumab (n=784) or placebo (n=390) plus standard therapy Efficacy: 36-mo-EFS: 84.5% [81.7%-86.9%] vs 76.8%
New Indication: Cemiplimab in Recurrent Cervical Cancer
Study: Open-label, multicenter, phase 3 trial (EMPOWER-Cervical 1) Recurrent or metastatic cervical carcinoma, progressed after prior platinum-containing therapy Cemiplimab (n=304) or single-agent chemotherapy (n=304) Efficacy: mOS: 12.0 mos vs. 8.5
New Indication: Nivolumab Combination in Advanced Esophageal Squamous-Cell Carcinoma
Study: Global, randomized, open-label, phase 3 trial (CheckMate 648) Unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma with no previous systemic therapy for advanced disease Nivolumab plus chemotherapy (n=321) or
New Indication: Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
Study: Multicenter, international, phase 2 study Metastatic HER2-mutant NSCLC, refractory to standard treatment Trastuzumab deruxtecan (N=91) Efficacy: mPFS: 8.2 mos, mOS:17.8 mos mDOR: 9.3 mos Safety: All patients had adverse
New Drug: Relatlimab and Nivolumab in Advanced Melanoma
Study: Double-blind, randomized Phase II-III trial Untreated metastatic or unresectable melanoma Relatlimab and nivolumab vs nivolumab alone Efficacy: mPFS: 10.1 vs 4.6 mos (HR:0.75; P=0.006) 12 months PFS: 47.7% vs
New Reference: Ribociclib plus Letrozole in Advanced Breast Cancer
Study: Randomized phase III trial (MONALEESA-2) Postmenopausal, HR-positive, HER2-negative recurrent or metastatic breast cancer with no previous systemic therapy for advanced disease Ribociclib or placebo in combination with letrozole Efficacy:
New Reference: Paclitaxel and Carboplatin for uterine carcinosarcoma
Study: International, randomized, open label, noninferiority phase III Chemotherapy-naïve uterine or ovarian carcinosarcoma CARBOplatin + PACLitaxel (n=228) or Ifosfamide + PACLitaxel (n=221) for 6-10 cycles Efficacy: For UCS: mOS: 37
New Indication: Trastuzumab, Pertuzumab, and Docetaxel in Advanced her2+ Non–Small-Cell Lung Cancer
Study: Multicenter, nonrandomized phase II study HER2-mutated, advanced NSCLC with ≥ one previous line including platinums Pertuzumab+trastuzumab+docetaxel (n=45) Efficacy: ORR: 29%, SD: 58% mPFS: 6.8 mos, mOS: 17.6 mos 5
New Reference: DD-MVAC vs. GC in muscle-invasive bladder cancer
Study: Randomized phase II trial (GETUG-AFU V05 VESPER) Nonmetastatic muscle-invasive bladder cancer Dd-MVAC vs gemsitabin+cisplatin. Neoadjuvant OR adjuvant chemotherapy Efficacy: Organ confined response: 77% v 63% (p = 0.001) Neoadjuvant
New Protocol: Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer
Study: Multicenter, randomized controlled trial (PREOPANC) Resectable or borderline resectable pancreatic cancer 3 cycles of gemcitabine combined with RT (n=119) or upfront surgery plus adjuvant 4 cycles gemcitabine (n=127) Efficacy:
New Indication: Cabozantinib Plus Nivolumab in non–Clear-Cell RCC
Study: Single-arm, phase 2 trial Non-clear cell RCC with 0-1 prior systemic therapies (n=47) Cabozantinib 40 mg once daily + nivolumab 240 mg/2 weeks or 480 mg/4 weeks Efficacy: Median
New Indication: Dabrafenib + trametinib for bRAF V600E mutant glioma
Study: Open-label, single-arm, phase 2, basket trial BRAFV600E mutation-positive high- low-grade glioma Prior radiotherapy and chemotherapy or chemoradiotherapy for high grade glioma Dabrafenib 150 mg twice daily plus trametinib 2
New Indication: Trastuzumab deruxtecan for her2+ NSCLC
Study: Multicenter, international, phase 2 study Metastatic HER2-mutant NSCLC (refractory to standard treatment) Trastuzumab deruxtecan >= 6.4 mg per kilogram of body weight Efficacy: ORR: 55% (95% CI, 44 to
New Protocol: Polatuzumab-R-CHP for DLBCL
Study: Double-blind Phase III trial Untreated intermediate-risk or high-risk DLBCL Polatuzumab-R-CHP vs R-CHOP Efficacy: 2 years PFS: 76.7% vs 70.2% (HR:0.73 95% Cl 0.57-0.95 p=0.02) 2 years OS: 88.7% vs
New Protocol: Panitumumab + FU/FA for maintenance in colorectal cancer
Study: Open-label randomized trial (AIO KRK 0212) RAS Wild-type metastatic colorectal cancer Post first-line induction therapy with six cycles of FU/FA and oxaliplatin plus Pmab FU/FA plus Pmab or FU/FA
New Drug: Tebentafusp-tebn for metastatic uveal melanoma
Study: Open-label Phase III trial Untreated HLA-A*02:01-positive patients with metastatic uveal melanoma Tebentafusp or the investigator’s choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine Efficacy: Median OS: 21.7 vs.
New Protocol: SubQ daratumumab – carfilzomib – dexamethasone for myeloma
Study: Single arm cohort study Relapsed or refractory multiple myeloma Prior 1 to 3 lines therapy Daratumumab 1800 mg SC, hyaluronidase 30000 units SC, carfilzomib IV and dexamethasone peroral Efficacy: